The Use of Home Spirometry in Pediatric Cystic Fibrosis Patients: Results of a Feasibility Study

Aarti Shakkottai, Samya Z Nasr, Aarti Shakkottai, Samya Z Nasr

Abstract

Medication adherence is poor among pediatric cystic fibrosis (CF) patients, with adolescents having one of the lowest adherence rates. We wanted to identify an adherence intervention that would be acceptable to CF adolescents and assess its feasibility. We surveyed 40 adolescents with CF and asked about barriers to and motivators for their own adherence and to generate ideas for potential adherence interventions. Since most of the respondents chose frequent spirometry at home and medication reminders for interventions, we selected 5 subjects, 10 to 14 years of age, with CF to test the feasibility of home spirometry and medication reminders in pediatric CF patients. This article summarizes the results of both the survey and the feasibility pilot study.

Keywords: adherence; adolescents; cystic fibrosis; home spirometry.

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Barriers to adherence as reported by the survey respondents.
Figure 2.
Figure 2.
Motivators for adherence as reported by the survey respondents.
Figure 3.
Figure 3.
Interventions for improving adherence suggested by our survey respondents.
Figure 4.
Figure 4.
Mean medication possession ratios for inhaled hypertonic saline, dornase alfa, and CF multivitamins in the intervention and control groups at baseline and end of study.

References

    1. Cystic Fibrosis Foundation Patient Registry. 2014 Annual data report. Bethesda, MD: Cystic Fibrosis Foundation; 2015.
    1. Sawicki GS, Goss CH. Tackling the increasing complexity of CF care. Pediatr Pulmonol. 2015;50(suppl 40):S74-S79.
    1. Shakkottai A, Kidwell KM, Townsend M, Nasr SZ. A five-year retrospective analysis of adherence in cystic fibrosis. Pediatr Pulmonol. 2015;50:1224-1239.
    1. Quittner AL, Zhang J, Marynchenko M, et al. Pulmonary medication adherence and health-care use in cystic fibrosis. Chest. 2014;146:142-151.
    1. Eakin MN, Bilderback A, Boyle MP, Mogayzel PJ, Riekert KA. Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros. 2011;10:258-264.
    1. Rosenfeld M, VanDevanter DR, Ren CL, et al. ; Investigators of Coordinators of the Epidemiologic Study of Cystic Fibrosis. Decline in lung function does not predict future decline in lung function in cystic fibrosis patients. Pediatr Pulmonol. 2015;50:856-862.
    1. Cogen J, Emerson J, Sanders DB; EPIC Study Group. Risk factors for lung function decline in a large cohort of young cystic fibrosis patients. Pediatr Pulmonol. 2015;50:763-770.
    1. Dziuban EJ, Saab-Abazeed L, Chaudhry SR, Streetman DS, Nasr SZ. Identifying barriers to treatment adherence and related attitudinal patterns in adolescents with cystic fibrosis. Pediatr Pulmonol. 2010;45:450-458.
    1. George M, Rand-Giovannetti D, Eakin MN, Borrelli B, Zettler M, Riekert KA. Perceptions of barriers and facilitators: self-management decisions by older adolescents and adults with CF. J Cyst Fibros. 2010;9:425-432.
    1. Bregnballe V, Schiøtz PO, Boisen KA, Pressler T, Thastum M. Barriers to adherence in adolescents and young adults with cystic fibrosis: a questionnaire study in young patients and their parents. Patient Prefer Adherence. 2011;5:507-515.
    1. Goodfellow NA, Hawwa AF, Reid AJ, Horne R, Shields MD, McElnay JC. Adherence to treatment in children and adolescents with cystic fibrosis: a cross-sectional, multi-method study investigating the influence of beliefs about treatment and parental depressive symptoms. BMC Pulm Med. 2015;15:43.
    1. Sawicki GS, Heller KS, Demars N, Robinson WM. Motivating adherence among adolescents with cystic fibrosis: youth and parent perspectives. Pediatr Pulmonol. 2015;50:127-136.
    1. Finkelstein SM, Wielinski CL, Kujawa SJ, Loewenson R, Warwick WJ. The impact of home monitoring and daily diary recording on patient status in cystic fibrosis. Pediatr Pulmonol. 1992;12:3-10.
    1. Lechtzin N, West N, Allgood S, et al. Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial. Contemp Clin Trials. 2013;36:460-469.
    1. Johnson KB, Culpepper D, Scott P, Gordon JS, Harris C. The utility of providing automated medication dose reminders to young children on chronic medication. J Telemed Telecare. 2011;17:387-391.
    1. Modi AC, Quittner AL. Validation of a disease-specific measure of health-related quality of life for children with cystic fibrosis. J Pediatr Psychol. 2003;28:535-545.
    1. Quittner AL, Buu A, Messer MA, Modi AC, Watrous M. Development and validation of the Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest. 2005;128:2347-2354.
    1. Quittner AL, Sawicki GS, McMullen A, et al. Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample. Qual Life Res. 2012;21:1267-1278.
    1. Quanjer PH, Weiner DJ, Pretto JJ, Brazzale DJ, Boros PW. Measurement of FEF25-75% and FEF75% does not contribute to clinical decision making. Eur Respir J. 2014;43:1051-1058.
    1. Lukic KZ, Coates AL. Does the FEF25-75 or the FEF75 have any value in assessing lung disease in children with cystic fibrosis or asthma? Pediatr Pulmonol. 2015;50:863-868.
    1. Habib AR, Manji J, Wilcox PG, et al. A systematic review of factors associated with health-related quality of life in adolescents and adults with cystic fibrosis. Ann Am Thorac Soc. 2015;12:420-428.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi